Sk3 Group, Inc. (PC) (SKTO
Seite 4 von 4 Neuester Beitrag: 24.04.21 23:24 | ||||
| Eröffnet am: | 12.01.14 15:49 | von: einstein16 | Anzahl Beiträge: | 91 |
| Neuester Beitrag: | 24.04.21 23:24 | von: Monikansufa | Leser gesamt: | 17.886 |
| Forum: | Hot-Stocks | Leser heute: | 11 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | > | ||||
Optionen
| Boardmail an "einstein16" |
Wertpapier: SK3 GROUP INC |
schönen tag noch.
Optionen
| Boardmail an "einstein16" |
Wertpapier: SK3 GROUP INC |
Optionen
| Boardmail an "einstein16" |
Wertpapier: SK3 GROUP INC |
Optionen
| Boardmail an "Obelax" |
Wertpapier: SK3 GROUP INC |
Date : 02/14/2014 @ 10:50AM
Source : Marketwired
Stock : Sk3 Group, Inc. (PC) (SKTO)
Quote : 0.0462 0.0068 (17.26%) @ 3:44PM
SK3 Group's (OTC-PINK: SKTO) Medical Greens Is Pleased to Announce That the First Bottles of Dharmanol(TM) Are Shipping & Wil...
Sk3 Group, Inc. (PC) (USOTC:SKTO)
Intraday Stock Chart
Today : Friday 14 February 2014
SK3 Group's (OTC-PINK: SKTO) Medical Greens Is Pleased to Announce That the First Bottles of Dharmanol(TM) Are Shipping and Will Be Immediately Available on www.pharmajanes.com Among Other Places
LOS ANGELES, CA--(Marketwired - Feb 14, 2014) - SK3 Group, Inc's (OTC Pink: SKTO) subsidiary Medical Greens is pleased to announce that the first bottles of Dharmanol™ Whole Plant tablets, for which Medical Greens has the exclusive license, are shipping today. Dharmanol™ is a medical cannabis-based supplement that contains all of the natural elements of the cannabis/hemp plant that are thought to promote healing, with the exception of THC, the molecule which is responsible for the psychoactive effect -- or "high" -- of marijuana.
Dharmanol™, developed by David Hoye and Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories, contains under .03% THC, less than many hemp-based health products that are sold at stores such as Costco and Walgreens. But it contains 10 mg. of the non-psychoactive phyto-cannabinoids that are present in hemp/cannabis, and are thought to contribute to the myriad of mechanisms that many university-level scientific studies have shown to be responsible for the remarkable healing power of medical marijuana.
Dharmanol™ tablets will be available soon in California through AEGY's www.pharmajanes.com delivery service and select medicinal marijuana dispensaries.
Dharmanol™ is sold in a bottle of 8 tablets. The suggested retail price for a bottle is $25.00. Each tablet contains 5 mg. cannabidiol (CBD), 5 mg. of non-psychoactive mixed carboxylates of the primary cannabinoids, 5 mg. of mixed separated terpenes and terpenoids of cannabis/hemp, 25 mg. of organic cold-pressed hemp oil, and 25 mg. of vitamin C (ascorbic acid as a preservative).
Dharmanol Citrolene™ will be released shortly. This formulation combines the phyto-cannabinoid formula found in Dharmanol™ with a substantial dose of the terpene d-Limonene. D-Limonene is found in cannabis/hemp, but also present in the rinds of certain citrus fruits. D-Limonene has been shown to bind with the same receptors as benzodiazapines such as Valium and Xanax, producing a pronounced relaxing and anti-spasmodic effect, without the negative side effects that many attribute to the synthetic pharmaceuticals.
"We are pleased to be able to start delivering this important product to market through our distribution network of dispensaries and our related web-based delivery service www.pharmajanes.com," said Artemus Mayor, President of SK3 Group, Inc. "These products are industry leading and will allow us to deliver the health benefits of medical marijuana to more patients who will not have to worry about feeling 'high' after their use. These products will contribute directly to our topline revenue growth."
FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Medical Greens
investors@medicalgreens.com
Investor Relations
Optionen
| Boardmail an "Obelax" |
Wertpapier: SK3 GROUP INC |
Optionen
| Boardmail an "Obelax" |
Wertpapier: SK3 GROUP INC |
Angehängte Grafik:
image.jpg (verkleinert auf 70%)
image.jpg (verkleinert auf 70%)
Optionen
| Boardmail an "Money is King" |
Wertpapier: SK3 GROUP INC |
Optionen
| Boardmail an "Obelax" |
Wertpapier: SK3 GROUP INC |
Optionen
| Boardmail an "einstein16" |
Wertpapier: SK3 GROUP INC |
Optionen
| Boardmail an "einstein16" |
Wertpapier: SK3 GROUP INC |
Investment Report Written by Mark Bonacci,
Chief Financial Analyst
Mark Bonacci has worked on Wall Street for several years in various financial services roles and is a self-
employed investment analyst and equity trader
SK3 Group, Inc. (OTCBB : SKTO) Growth with Foresight
Published April 14, 2014
Research Report
Company operations
SKTO has been engaged in the cannabis industry, mainly providing administrative services to marijuana
collectives in California, since 2010. Starting last year the company moved further into the cannabis
industry through mergers and acquisitions that place them in the marijuana products, distribution and
real estate businesses.
Products currently licensed by SK3 Group exclusively for marketing and sale include:
YAK
The YAK line of medical marijuana edibles consists of the “Greenie” cookie, "Haute Chocolate" (an
instant chocolate drink), "Mocha-Juana" (an instant chocolate/coffee drink), and "Whole Plant Cannabis
Extract Capsules" in Indica, Sativa and High-CBD. There is also medicated chocolate taffy which is
available in Indica, Sativa, Hybrid, and High-CBD. YAK also produces Red Diamond Oil used for needs
such as pain relief.
CANNA-LOZ
Canna-Loz™ is a delivery system for large doses of phyto-cannabinoids, as used in the “Simpson”
therapy, and a new product line utilizing this delivery system. Canna-Loz™ is a soft lozenge containing
250 mg. of whole-plant cannabis extract oil, with approximately 50% cannabinoids, mainly THC and CBD,
but with all of the lesser cannabinoids, as well as the entire array of terpenes and terpenoids.
YETI
This is a premium quality pre-roll for pain relief. It is high-quality cannabis flowers which have been
impregnated with Red Diamond oil.
DHARMANOL
Cannabinoids are a natural substance with medicinal benefits found in cannabis. The most well-known is
tetrahydrocannabinol, or THC. THC is responsible for the physical and mental effects (the "high")
associated with smoking marijuana. Other cannabinoids (there are over 60 in a single plant) such as
cannabidiol (CBD) have been shown to have substantial medicinal value while producing no noticeable
psychoactive effects. High-CBD cannabis tinctures, capsules and edibles, a sublingual spray, and infused
vegetable oils. Medical Greens will oversee quality control and provide testing for cannabinoid content
and microbiological purity.
CANNABEE PRODUCT
The Company is the authorized licensed distributor for this line of products through our collectives,
which includes:
eJoint eVaporizingTM system holds the distinction of being the first ever e-cigarette intended for the use
of medicinal infusions and extractions.
GoPureVXTM is the first vapor-optimized cannabis oil.
CannaSpaTM is a line of infused topical remedies.
The addition of PharmaJane’s online ordering system and simple payment solutions product will be a
good blend for SKTO, taking their products from the consumers communication device screen and
literally delivering to their door.
Company Developments
Alternative Energy Partners, Inc., doing business as PharmaJanes, and SK3 Group, doing business as
Medical Greens, have signed a definitive agreement to merge the two companies for better market
efficiencies and to create a single medical marijuana market support company which can qualify for a
higher (AMEX, NASDAQ) market listing.
SKTO and AEGY will merge into a newly formed acquisition company. Shareholders of each company will
receive shares of the new holding company, which will succeed to the SEC reporting obligation of AEGY
and which will apply for a new trading symbol, a new CUSIP number, and continued electronic trading
status with the Depository Trust Company. The final exchange rate for the common shares of AEGY and
SKTO will be based on the volume weighted average market value of each company on the effective
date, which has not yet been determined.
AEGY's PharmaJanes™ provides patient enrollment in its network of dispensaries by processing and
verifying patients' applications. PharmaJanes™ routes customer orders to its exclusive non-profit
collectives, which then process and deliver the orders to patients in their homes. PharmaJanes™
features products produced by master growers, and products licensed by SKTO to its wholesale
managed collectives.
SK3 Group's Medical Greens subsidiary now has an additional new distributor in the San Francisco Bay
Area in California for its wholesale managed collective portfolio. This step increases the reach of its
wholesale managed collective portfolio into additional medical cannabis dispensaries and delivery
services for its various product lines. The total population of the San Francisco Bay Area is over 7.1
million people, making it the second most populous urban area in California after the Greater Los
Angeles area, and the fifth largest in the United States.
Financial and Share Structure
Revenue jumped from $5 million in the quarter ended 3-31-13 to $13 million in the quarter ended 6-30-
13. Assets increased from $5 million to $18 million for the same two quarters, consisting mainly of
receivables and no cash.
For the quarter ended 9-30-13 the company released preliminary figures showing that on a consolidated
basis the Company with its subsidiaries, will be reporting approximate revenue and deferred revenue in
excess of $13,000,000 for the quarter ending September 30, 2013. Receivables collected during the
quarter will exceed $300,000 compared to $42,229 for the previous quarter and the consolidated cash
balances are $125,000 compared to $-0- for the June quarter.
The company has 750,000,000 shares of common stock authorized and 601,500,303 common shares
outstanding. These figures are from last year and the merger with AEGY could have affected them.
Conclusion
SKTO is making all the right moves to gain a foothold in the cannabis industry. Growth through merger
and acquisition has to be the theme for success for the plethora of OTC companies making recent entry
into the marijuana market space.
The company is going to face the same hurdles as others of their ilk will face. Can management keep up
with the growth and diversity of the combined entities? Management conflicts and personnel strains,
along with cohesive branding issues and communications can often outweigh the synergies these
combinations create. If management can put all these marijuana businesses together, buying cannabis
products could be as easy and effective as buying stuff on e-Bay or Amazon.
The volume of shares that are issued to create these companies can be huge and dilute the shares to the
point where shareholders lose the benefit, if even temporarily, of ownership.
SK3 seems to have aligned itself well. Effective distribution will be the hurdle for many of the companies
bringing new cannabis products to market. PharmaJanes seems to have cleared that hurdle in a user
friendly and effective way.
Sources
www.yahoofinance (news feed)
www.medicalgreens.com
Optionen
| Boardmail an "einstein16" |
Wertpapier: SK3 GROUP INC |